Haemoglobin mass in a female endurance athlete was measured via carbon monoxide rebreathing upon diagnosis of iron-deficiency anemia (haemoglobin concentration = 8.8 g/dL, ferritin = 9.9 ng/mL) and regularly during treatment thereafter. Haemoglobin mass increased by 49% in the 2 wk following an intramuscular iron injection and continued to increase with oral iron supplementation for 15 wk. The presented case illustrates that haemoglobin mass is readily responsive to iron supplementation in a severely iron-deficient anemic athlete and that changes can be tracked efficiently using the CO-rebreathing method.
Female distance runners may be at greater risk of iron depletion due to iron loss through foot-strike haemolysis, menstrual irregularities, and insufficient iron intake. In severe cases, iron depletion may develop into iron-deficiency anemia, with endurance performance severely impaired as a result of decreased oxygen transport capacity. 1 In clinical settings, hemoglobin concentration, [Hb] , and serum ferritin are typically used for diagnosis, yet they have limitations in elite athletes because both can be affected by training. 2, 3 Direct measurement of hemoglobin mass (Hb mass ) via carbon monoxide (CO) rebreathing has the advantage that is not affected by plasma volume shifts, 4 thereby providing an additional and robust diagnostic tool for the investigation of anemia in athletes.
The aim of the present study was to document changes in Hb mass following iron supplementation in a female endurance athlete diagnosed with iron-deficiency anemia. A female middle-distance runner (age 19 y, height 171 cm, mass 63 kg) presented with high levels of fatigue that were accompanied by a steady decrease in running performance and training ability over approximately 3 mo. Following medical examination, blood tests revealed severe iron-deficiency anemia characterized by low serum ferritin and accompanied by low [Hb] , decreased serum iron concentration, and decreased percent transferrin saturation (Table 1) . 5 Treatment consisted of an intramuscular iron injection under medical supervision (Ferrum H, Fe polymaltose, 100 mg Fe), followed by oral iron supplementation twice daily (FerroGradumet, 325 mg ferrous sulfate, 100 mg elemental Fe). Since parenteral iron therapy can reduce the absorption of oral iron, it is recommended that oral supplementation is not commenced until 1 wk after the last injection, and only after medical advice.
Haemoglobin mass was measured in duplicate before and repeatedly following iron supplementation using the optimized CO-rebreathing technique, 3, 4 until Hb mass was deemed to have stabilized. The typical error (TE) of the method is 1.1-2.0%. 3, 4, 6 Briefly, a CO bolus of 0.8-1.2 mL⋅kg -1 was rebreathed for 2 min. The percentage of HbCO in the blood was measured via capillary finger-tip samples (200 µL) before and 7 min after administration of the CO dose and analyzed immediately in quintuplet using an OSM3 hexiometer (Radiometer, Copenhagen, Denmark). Due to the very low [Hb] of the initial blood screen, the volume of CO administered at the start of the monitoring period was 0.8 mL⋅kg -1 , but was increased to the optimal dose of 1.2 mL⋅kg -1 in accordance with changes in Hb mass . Hemoglobin concentration and iron status were determined from venous blood collected from Figure 1 .
Discussion
Haemoglobin mass increased markedly and rapidly in response to intramuscular iron supplementation, and thereafter continued to increase with oral iron supplementation. Upon initial presentation, the athlete's Hb mass was 389 g, equivalent to 6.2 g⋅kg -1 and consistent with the diagnosis of iron-deficiency anemia-the normal range for a female endurance athlete being 10-13 g⋅kg -1 . 6 Two weeks after the iron injection, Hb mass increased by 49% to 580 g or 9.3 g⋅kg -1 . Seven weeks postinjection, Hb mass increased an additional 110 g to 690 g, or 77% above the initial value. At 10.9 g⋅kg -1 , the athlete's Hb mass was within the normal range for a female endurance athlete. The athlete was gradually able to resume her usual training volume (∼80 km⋅wk -1 ) and intensity over the intervention period and recorded a personal best time over 3000 m at ∼70 days postinjection. Both Hb mass and [Hb] appeared to reach a plateau 15 wk after treatment began at ∼700 g and 13.0 g⋅dL -1 , respectively. The influence of changes in training load during the monitoring period should be considered in relation to the observed increase in Hb mass . Changes in Hb mass have been related to changes in 6 wk training load in elite cyclists. 6 During the early stages of treatment, only minimal low-intensity training sessions were completed; however, at 6 wk postinjection training load was progressively increased with "normal" training resumed by 15 wk. Therefore, as the athlete responded to treatment and was able to increase her training load, it is possible that an additional erythropoietic stimulus was gained from training per se. However, changes in Hb mass arising from even dramatic (100%) changes in training load over 6 wk are unlikely to exceed ∼10%, 6 implying that the majority of changes observed in this runner, and certainly those in the initial intervention period, can be attributed to iron supplementation. In addition, while the performance improvement is very likely due to the change in Hb mass , the minimal low-intensity training performed at the start of treatment could be considered a "taper" that may partially explain some of the performance recovery. 7 The present case illustrates that Hb mass is readily responsive to iron supplementation in a severely iron-deficient anemic athlete and that changes are tracked efficiently using the CO-rebreathing method. Measurement of Hb mass , in addition to [Hb] and iron parameters, represents another valuable diagnostic and monitoring tool for anemic conditions. Hb mass measurement has the advantage that it is independent of changes in plasma volume and therefore can be performed at any time of day, irrespective of training or nutritional status. Furthermore, the technique may be more sensitive to subtle changes in total hemoglobin content, and thus oxygen carrying capacity, which may have significant effects for endurance performance. This is illustrated by the changes in Hb mass and [Hb] observed in the athlete in the later stages of treatment where Hb mass continued to increase whereas [Hb] remained constant.
The presented case confirms the effectiveness of iron supplementation in the treatment of iron-deficiency anemia and provides some additional insight into the time course of the erythropoietic response to treatment. From an antidoping perspective, iron status and supplementation, particularly in female athletes, should be considered in reference to longitudinal monitoring of Hb mass and blood parameters over time. 4 
